Patents by Inventor Ryotaro Mitsumata

Ryotaro Mitsumata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240156943
    Abstract: An influenza vaccine that has high immunogenicity in children and elderly people and has a higher efficacy than conventional split vaccines. An influenza vaccine composition to be administered to children and/or elderly people, including, as a virus antigen, inactivated whole particles subjected to inactivation treatment with beta-propiolactone.
    Type: Application
    Filed: March 29, 2022
    Publication date: May 16, 2024
    Applicant: DENKA COMPANY LIMITED
    Inventors: Ryotaro MITSUMATA, Tomohiro NARAHARA
  • Patent number: 11890338
    Abstract: An inactivated whole-virus influenza vaccine may have its antibody-inducing ability is maintained or enhanced and may cause fewer side reactions. A method for preparing an inactivated whole-virus influenza vaccine may use an embryonated chicken egg method, including subjecting a virus solution including a whole influenza virus collected from embryonated chicken eggs to a hypotonic treatment.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: February 6, 2024
    Assignees: DENKA COMPANY LIMITED, NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
    Inventors: Ryotaro Mitsumata, Shogo Misumi, Naoki Kishimoto, Takuma Gotanda, Nagisa Nakata
  • Publication number: 20230330221
    Abstract: Provided are an adjuvant useful for preparing a vaccine having high efficacy and high safety, and a vaccine composition comprising the adjuvant. The adjuvant comprises a peptide nucleic acid to which a cell penetrating peptide is bound.
    Type: Application
    Filed: June 5, 2020
    Publication date: October 19, 2023
    Applicant: DENKA COMPANY LIMITED
    Inventors: Ryotaro MITSUMATA, Asumi KANDA
  • Patent number: 11707521
    Abstract: A mucosal adjuvant may have high mucosal immunogenicity and high safety and be useful in the preparation of mucosal vaccines, and a mucosal vaccine composition may include the same. Such mucosal adjuvant may include TGDK. A method for preparing the mucosal vaccine composition may include mixing TGDK with an immunogen.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: July 25, 2023
    Assignees: DENKA COMPANY LIMITED, NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
    Inventors: Shogo Misumi, Naoki Kishimoto, Ryotaro Mitsumata, Nagisa Nakata, Takuma Gotanda
  • Publication number: 20230147269
    Abstract: An inactivated influenza vaccine may have high immunogenicity and may be produced by method including performing inactivation treatment using formaldehyde including treating a virus solution containing an influenza virus collected from a host with ?-propiolactone in advance. The inactivation treatment using formaldehyde may be performed by adding formalin to the virus solution at a final concentration of 0.005 to 0.015 vol %.
    Type: Application
    Filed: February 25, 2021
    Publication date: May 11, 2023
    Applicant: DENKA COMPANY LIMITED
    Inventors: Ryotaro MITSUMATA, Keiko YOSHIDA
  • Publication number: 20220331419
    Abstract: Provided is a seasonal influenza vaccine having a higher efficacy than a split vaccine. A seasonal influenza vaccine which induces virus-specific antibodies in the nasal mucosa, comprises inactivated whole influenza virus particles as an active ingredient, and is to be administered intradermally at dose per administration of 15 ?g HA or more per strain as antigen.
    Type: Application
    Filed: September 2, 2020
    Publication date: October 20, 2022
    Applicant: DENKA COMPANY LIMITED
    Inventors: Ryotaro MITSUMATA, Asumi KANDA, Nagisa NAKATA, Shigetaka MIMORI
  • Publication number: 20220288224
    Abstract: Provided is a pharmaceutical agent for enhancing absorption efficiency of a drug through the mucosal epithelial layer. A pharmaceutical agent for transmucosal administration comprises as an active ingredient a drug compound to which a podocalyxin targeting molecule is bound.
    Type: Application
    Filed: August 4, 2020
    Publication date: September 15, 2022
    Applicants: DENKA COMPANY LIMITED, NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
    Inventors: Shogo MISUMI, Naoki KISHIMOTO, Ryotaro MITSUMATA
  • Publication number: 20220031838
    Abstract: A mucosal adjuvant may have high mucosal immunogenicity and high safety and be useful in the preparation of mucosal vaccines, and a mucosal vaccine composition may include the same. Such mucosal adjuvant may include TGDK. A method for preparing the mucosal vaccine composition may include mixing TGDK with an immunogen.
    Type: Application
    Filed: September 26, 2019
    Publication date: February 3, 2022
    Applicants: DENKA COMPANY LIMITED, NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
    Inventors: Shogo MISUMI, Naoki KISHIMOTO, Ryotaro MITSUMATA, Nagisa NAKATA, Takuma GOTANDA
  • Publication number: 20220031833
    Abstract: An inactivated whole-virus influenza vaccine may have its antibody-inducing ability is maintained or enhanced and may cause fewer side reactions. A method for preparing an inactivated whole-virus influenza vaccine may use an embryonated chicken egg method, including subjecting a virus solution including a whole influenza virus collected from embryonated chicken eggs to a hypotonic treatment.
    Type: Application
    Filed: September 26, 2019
    Publication date: February 3, 2022
    Applicants: DENKA COMPANY LIMITED, NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
    Inventors: Ryotaro MITSUMATA, Shogo MISUMI, Naoki KISHIMOTO, Takuma GOTANDA, Nagisa NAKATA
  • Patent number: 10365277
    Abstract: Disclosed is a novel method for measuring haemagglutinin of an influenza virus, which can construct an assay system in a shorter period of time than a sandwich immunoassay method using two kinds of anti-haemagglutinin antibodies. The method for measuring haemagglutinin of an influenza virus is achieved by a sandwich immunoassay method comprising sandwiching the haemagglutinin between a lectin which binds to the haemagglutinin but does not bind to an antibody, and an anti-haemagglutinin antibody which undergoes antigen-antibody reaction with the haemagglutinin.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: July 30, 2019
    Assignee: DENKA SEIKEN CO., LTD.
    Inventors: Ryotaro Mitsumata, Noriyuki Izutani
  • Publication number: 20150233922
    Abstract: Disclosed is a novel method for measuring haemagglutinin of an influenza virus, which can construct an assay system in a shorter period of time than a sandwich immunoassay method using two kinds of anti-haemagglutinin antibodies. The method for measuring haemagglutinin of an influenza virus is achieved by a sandwich immunoassay method comprising sandwiching the haemagglutinin between a lectin which binds to the haemagglutinin but does not bind to an antibody, and an anti-haemagglutinin antibody which undergoes antigen-antibody reaction with the haemagglutinin.
    Type: Application
    Filed: October 3, 2013
    Publication date: August 20, 2015
    Applicant: DENKA SEIKEN CO., LTD.
    Inventors: Ryotaro Mitsumata, Noriyuki Izutani